Supplementation with antioxidant vitamins C and E for the prevention of pre-eclampsia: a randomised controlled trial.

Alice Rumbold
Department of Obstetrics and Gynaecology
Faculty of Health Sciences
The University of Adelaide
June 2005
TABLE OF CONTENTS

1. LITERATURE REVIEW ........................................................................................................1

1.1 Introduction.....................................................................................................................1

1.2 Definition of pre-eclampsia............................................................................................2

1.3 Outcomes for women with pre-eclampsia and their infants.........................................4

1.4 Risk factors and screening for pre-eclampsia...............................................................5

1.5 Aetiology and pathogenesis of pre-eclampsia..............................................................7

1.6 Oxidative stress .............................................................................................................9
  1.6.1 Oxidative stress in pre-eclampsia .............................................................................11
  1.6.2 Circulating markers of oxidative stress .................................................................12
  1.6.3 Placental markers of oxidative stress ......................................................................16
  1.6.4 Oxidative stress and endothelial cell activation ....................................................19
  1.6.5 Summary .................................................................................................................20

1.7 Dietary intake of antioxidants .....................................................................................22

1.8 Vitamin C and E ..........................................................................................................24
  1.8.1 Optimal intakes of vitamin C and E ......................................................................27
  1.8.2 Safety and adverse effects of vitamin C supplementation ....................................28
  1.8.3 Safety and adverse effects of vitamin E supplementation ....................................29
  1.8.4 Systematic review of vitamin C and E supplementation in pregnancy .............31
  1.8.5 Summary .................................................................................................................32

1.9 Conclusions .................................................................................................................32

2. SYSTEMATIC REVIEW OF ANTIOXIDANTS FOR THE PREVENTION OF
   PRE-ECLAMPSIA ............................................................................................................33

2.1 Introduction ..................................................................................................................33

2.2 Cochrane systematic review: "Antioxidants for preventing pre-eclampsia"..............34
  2.2.1 Description of the review .......................................................................................34
  2.2.1.1 Objectives ..........................................................................................................34
  2.2.1.2 Criteria for inclusion of studies .........................................................................34
  2.2.1.3 Participants and subgroups ...............................................................................35
  2.2.2 Health outcomes specified in the review ...............................................................36
  2.2.2.1 Primary outcomes .............................................................................................36
  2.2.2.2 Secondary outcomes .........................................................................................36
  2.2.3 Search strategy for identification of studies ...........................................................37
  2.2.4 Methods of the review ..........................................................................................38
  2.2.5 Description of studies ..........................................................................................40
  2.2.5.1 Interventions .....................................................................................................41
  2.2.5.2 Primary outcomes .............................................................................................41
  2.2.5.3 Secondary outcomes .........................................................................................42
  2.2.5.4 Excluded trials ..................................................................................................42
  2.2.5.5 Methodological quality of included studies ....................................................43
  2.2.6 Results ....................................................................................................................44

- iii -
3.3 Methods ................................................................. 62
3.3.1 Participants ......................................................... 63
3.3.2 Randomisation, treatment pack preparation and allocation .......... 63
3.3.2.1 Generation of random number sequence ......................... 63
3.3.2.2 Treatment pack preparation ....................................... 63
3.3.3 Treatment group allocation ...................................... 64
3.3.4 Recruitment procedures ......................................... 64
3.3.5 Treatment Schedules .............................................. 65
3.3.6 Assessment of compliance with the trial Treatment Schedules ......... 66
3.3.7 Care during the Antenatal Period, Labour and Postnatal Stay .......... 66
3.3.8 Primary outcomes .................................................. 67
3.3.9 Secondary outcomes .............................................. 68
3.3.10 Subsidiary outcomes .............................................. 69
3.3.11 Data collection .................................................... 70
3.3.11.1 Pregnancy outcome data ......................................... 70
3.3.11.2 Trial questionnaires .............................................. 70
3.3.12 Sample size ........................................................ 71
3.3.13 Statistical analyses .............................................. 72
3.3.14 Adverse Events Committee ....................................... 73
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.4 Recruitment, flow of participants and maternal baseline characteristics</td>
<td>74</td>
</tr>
<tr>
<td>3.4.1 Unblinding of treatment group allocation</td>
<td>76</td>
</tr>
<tr>
<td>3.4.2 Maternal characteristics at trial entry</td>
<td>76</td>
</tr>
<tr>
<td>3.4.3 Women’s family history of hypertension and pre-eclampsia</td>
<td>78</td>
</tr>
<tr>
<td>3.4.4 Women’s use of dietary supplements</td>
<td>79</td>
</tr>
<tr>
<td>3.4.5 Women’s dietary intake of vitamin C and E at trial entry</td>
<td>79</td>
</tr>
<tr>
<td>3.4.6 Women’s use of dietary supplements at 28 weeks’ gestation</td>
<td>80</td>
</tr>
<tr>
<td>3.5 Women’s compliance with the trial tablets</td>
<td>81</td>
</tr>
<tr>
<td>3.5.1 Progress with the tablets from trial entry to 28 weeks’ gestation</td>
<td>81</td>
</tr>
<tr>
<td>3.5.2 Progress with the trial tablets after 28 weeks’ gestation</td>
<td>83</td>
</tr>
<tr>
<td>3.5.3 Overall compliance</td>
<td>85</td>
</tr>
<tr>
<td>3.6 Primary outcomes</td>
<td>86</td>
</tr>
<tr>
<td>3.7 Secondary maternal outcomes</td>
<td>88</td>
</tr>
<tr>
<td>3.8 Secondary infant outcomes</td>
<td>89</td>
</tr>
<tr>
<td>3.8.1 Preterm birth</td>
<td>89</td>
</tr>
<tr>
<td>3.8.2 Infant growth parameters</td>
<td>90</td>
</tr>
<tr>
<td>3.9 Subsidiary infant outcomes</td>
<td>91</td>
</tr>
<tr>
<td>3.10 Subsidiary maternal outcomes</td>
<td>93</td>
</tr>
<tr>
<td>3.10.1 Medications and health service utilisation</td>
<td>55</td>
</tr>
<tr>
<td>3.11 Potential side effects</td>
<td>96</td>
</tr>
<tr>
<td>3.11.1 Self reported side effects from trial entry to 28 weeks’ gestation</td>
<td>96</td>
</tr>
<tr>
<td>3.11.2 Self reported side effects after 28 weeks’ gestation</td>
<td>97</td>
</tr>
<tr>
<td>3.12 Women’s views on their participation</td>
<td>98</td>
</tr>
<tr>
<td>3.12.1 Women who stopped the trial medications early</td>
<td>98</td>
</tr>
<tr>
<td>3.12.2 Women who liked about being involved in the trial</td>
<td>99</td>
</tr>
<tr>
<td>3.12.3 Women who disliked about being involved in the trial</td>
<td>99</td>
</tr>
<tr>
<td>3.12.4 Women’s views on their perceived treatment group and future participation</td>
<td>100</td>
</tr>
<tr>
<td>3.13 Pre-specified subgroup analyses</td>
<td>101</td>
</tr>
<tr>
<td>3.13.1 Dietary intake of vitamin C at trial entry</td>
<td>101</td>
</tr>
<tr>
<td>3.13.2 Dietary intake of vitamin E at trial entry</td>
<td>102</td>
</tr>
<tr>
<td>3.13.3 Family history of hypertensive disorders in pregnancy</td>
<td>103</td>
</tr>
<tr>
<td>3.13.4 Smoking status at trial entry</td>
<td>104</td>
</tr>
<tr>
<td>3.13.5 Gestational age at trial entry</td>
<td>105</td>
</tr>
<tr>
<td>3.13.6 Blood pressure at trial entry</td>
<td>106</td>
</tr>
<tr>
<td>3.13.7 Compliance with the trial tablets</td>
<td>108</td>
</tr>
<tr>
<td>3.14 Discussion</td>
<td>110</td>
</tr>
<tr>
<td>3.14.1 Mechanisms of action for improved infant health</td>
<td>110</td>
</tr>
<tr>
<td>3.14.2 Impact of supplementation on the risk of pre-eclampsia</td>
<td>114</td>
</tr>
<tr>
<td>3.14.3 Safety of vitamin C and E supplementation in pregnancy</td>
<td>120</td>
</tr>
<tr>
<td>3.14.4 Women’s views on participating in this research</td>
<td>120</td>
</tr>
<tr>
<td>3.14.5 Statistical power of this trial</td>
<td>121</td>
</tr>
<tr>
<td>3.15 Conclusions</td>
<td>122</td>
</tr>
<tr>
<td>3.15.1 Implications for practice</td>
<td>122</td>
</tr>
<tr>
<td>3.15.2 Implications for research</td>
<td>123</td>
</tr>
</tbody>
</table>
4. HYPERTENSIVE DISORDERS OF PREGNANCY

4.1 Introduction

4.1.1 Gestational hypertension

4.1.2 Pre-eclampsia

4.1.2.1 ASSHP criteria – the "inclusive definition"

4.1.2.2 Proteinuric hypertension – the "restrictive definition"

4.1.2.3 Clinical label of "pre-eclampsia"

4.1.3 Severe hypertensive disease

4.1.4 Proteinuria

4.2 Discussion

4.3 Conclusions

4.3.1 Implications for practice

4.3.2 Implications for research

5. UPDATED SYSTEMATIC REVIEW OF ANTIOXIDANTS FOR THE PREVENTION OF PRE-ECLAMPSIA

5.1 Introduction

5.2 Objectives and Methods of the review

5.3 Results

5.3.1 Pre-eclampsia

5.3.1.1 All trials

5.3.1.2 High quality trials only

5.3.2 Preterm birth

5.3.2.1 All trials

5.3.2.2 High quality trials only

5.3.3 Small for gestational age infants

5.3.3.1 All trials

5.3.3.2 High quality trials only

5.3.4 Baby death

5.3.4.1 All trials

5.3.4.2 High quality trials only

5.3.5 Secondary outcomes

5.3.6 Other subgroup analyses

5.4 Discussion

5.5 Conclusions

5.5.1 Implications for practice

5.5.2 Implications for research

6. SUMMARY CONCLUSIONS

6.1 Conclusions from the randomised controlled trial of vitamin C and E supplementation during pregnancy

6.1.1 Implications for practice

6.1.2 Implications for future research

6.2 Conclusions from the systematic review of supplementation with any antioxidants during pregnancy for the prevention of pre-eclampsia
ABSTRACT

Background: Oxidative stress has been implicated in the pathogenesis of pre-eclampsia. Supplementing women with the antioxidant vitamins C and E during pregnancy may help counteract oxidative stress and thereby reduce the risk of pre-eclampsia and its related complications.

Methods: 1,538 multiparous women between 14th and 21st weeks’ gestation were randomised to either supplementation with vitamin C and E (n=770) or placebo (n=768). Primary outcome measures were the risk of having a small for gestational age infant (birth weight < 10th centile), pre-eclampsia and death or serious adverse outcome for the infant.

Results: Women in each treatment group were comparable for all important baseline maternal characteristics. No difference was seen between treatment groups for the risk of the infant being born small for gestational age (vitamin group 66 [8.6%] vs. placebo 71 [9.4%], Relative Risk (RR) 0.92, 95% Confidence Intervals (CI) 0.67 to 1.27, p=0.614) or the risk of pre-eclampsia (vitamin group 60 [7.8%] vs. placebo group 51 [6.6%], RR 1.17, 95% CI 0.82 to 1.68, p=0.383). Supplementation with vitamin C and E was associated with a 30 percent reduction in the relative risk of death or serious adverse outcome for the infant (vitamin group 54 [7.0%] vs. placebo group 77 [10.0%], RR 0.70, upper 95% CI <0.93, p=0.021, one-tailed test). This was associated with an absolute risk reduction of three percent, whereby 33 women would need to take vitamin C and E supplements in pregnancy in order for one infant to benefit. Mean head circumference at birth was greater for infants in the vitamin C and E group (vitamin group 34.6 cm [SD 1.7] vs. placebo group 34.4 cm [SD 1.9], mean difference 0.18 cm, 95% CI 0.00 to 0.36, p=0.047), and these infants also had a reduced risk of developing respiratory distress syndrome (vitamin group 1 [0.1%] vs. placebo group 9 [1.2%], RR 0.11, 95% CI 0.01 to 0.87, p=0.011).

Conclusion: Vitamin C and E supplementation cannot be recommended as a prophylaxis for pre-eclampsia for nulliparous women. The impact of supplementation on the risk of death or adverse health outcomes for the infant, including respiratory morbidity, requires further confirmation.